262 related articles for article (PubMed ID: 17881972)
1. A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.
Yamada S; Ohyama K; Taguchi M; Takeshita A; Morita K; Takano K; Sano T
Neurosurgery; 2007 Sep; 61(3):580-4; discussion 584-5. PubMed ID: 17881972
[TBL] [Abstract][Full Text] [Related]
2. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions.
Thapar K; Scheithauer BW; Kovacs K; Pernicone PJ; Laws ER
Neurosurgery; 1996 Apr; 38(4):765-70; discussion 770-1. PubMed ID: 8692397
[TBL] [Abstract][Full Text] [Related]
3. Clinical features of silent corticotroph adenomas.
Alahmadi H; Lee D; Wilson JR; Hayhurst C; Mete O; Gentili F; Asa SL; Zadeh G
Acta Neurochir (Wien); 2012 Aug; 154(8):1493-8. PubMed ID: 22619024
[TBL] [Abstract][Full Text] [Related]
4. A clinicopathological and immunohistochemical study of clinically non-functioning pituitary adenomas: a single institutional experience.
Rishi A; Sharma MC; Sarkar C; Jain D; Singh M; Mahapatra AK; Mehta VS; Das TK
Neurol India; 2010; 58(3):418-23. PubMed ID: 20644271
[TBL] [Abstract][Full Text] [Related]
5. [Should silent corticotroph-cell adenoma be classified as a non-functional pituitary adenoma?].
Jouanneau E; Ducluzeau PH; Tilikete C; Borson-Chazot F; Trouillas J; Perrin G
Neurochirurgie; 2001 May; 47(2-3 Pt 1):128-32. PubMed ID: 11404683
[TBL] [Abstract][Full Text] [Related]
6. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein alpha subunit (gsp) mutation in human GH-secreting pituitary adenomas.
Morita K; Takano K; Yasufuku-Takano J; Yamada S; Teramoto A; Takei M; Osamura RY; Sano T; Fujita T
Clin Endocrinol (Oxf); 2008 Mar; 68(3):435-41. PubMed ID: 18070145
[TBL] [Abstract][Full Text] [Related]
7. Clinically non-functioning human pituitary adenomas.
Asa SL; Kovacs K
Can J Neurol Sci; 1992 May; 19(2):228-35. PubMed ID: 1623451
[TBL] [Abstract][Full Text] [Related]
8. Correlation between histological subtypes and MRI findings in clinically nonfunctioning pituitary adenomas.
Nishioka H; Inoshita N; Sano T; Fukuhara N; Yamada S
Endocr Pathol; 2012 Sep; 23(3):151-6. PubMed ID: 22569896
[TBL] [Abstract][Full Text] [Related]
9. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic correlates of giant pituitary adenomas.
Chacko G; Chacko AG; Lombardero M; Mani S; Seshadri MS; Kovacs K; Scheithauer BW
J Clin Neurosci; 2009 May; 16(5):660-5. PubMed ID: 19285407
[TBL] [Abstract][Full Text] [Related]
11. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
12. The pathology of nonfunctional pituitary adenomas.
Martinez AJ
Semin Diagn Pathol; 1986 Feb; 3(1):83-94. PubMed ID: 3303231
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review.
Sahli R; Christ ER; Seiler R; Kappeler A; Vajtai I
Pathol Res Pract; 2006; 202(6):457-64. PubMed ID: 16497445
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2 expression correlates with cavernous sinus invasion in pituitary adenomas.
Liu W; Kunishio K; Matsumoto Y; Okada M; Nagao S
J Clin Neurosci; 2005 Sep; 12(7):791-4. PubMed ID: 16198918
[TBL] [Abstract][Full Text] [Related]
15. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
16. Morphological study of clinically nonsecreting pituitary adenomas in patients under 40 years of age.
Yamada S; Kovacs K; Horvath E; Aiba T
J Neurosurg; 1991 Dec; 75(6):902-5. PubMed ID: 1941118
[TBL] [Abstract][Full Text] [Related]
17. Silent corticotroph adenomas have unique recurrence characteristics compared with other nonfunctioning pituitary adenomas.
Cho HY; Cho SW; Kim SW; Shin CS; Park KS; Kim SY
Clin Endocrinol (Oxf); 2010 May; 72(5):648-53. PubMed ID: 19650787
[TBL] [Abstract][Full Text] [Related]
18. The expression of ghrelin in somatotroph and other types of pituitary adenomas.
Wasko R; Jaskula M; Kotwicka M; Andrusiewicz M; Jankowska A; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2008 Dec; 29(6):929-38. PubMed ID: 19112387
[TBL] [Abstract][Full Text] [Related]
19. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
Trouillas J; Labat-Moleur F; Sturm N; Kujas M; Heymann MF; Figarella-Branger D; Patey M; Mazucca M; Decullier E; Vergès B; Chabre O; Calender A;
Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
[TBL] [Abstract][Full Text] [Related]
20. Neuronal differentiation and expression of neural epitopes in pituitary adenomas.
Johnson MD; Fan X; Bourne P; Walters D
J Histochem Cytochem; 2007 Dec; 55(12):1265-71. PubMed ID: 17875653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
